SGLT2 inhibitors and GLP-1 receptor agonists show promise across the interconnected spectrum of obesity, diabetes, kidney disease, and heart failure.
Multi-organBoth SGLT2 inhibitors and GLP-1 RAs provide benefits across heart, kidney, and metabolic systems simultaneously
What the researchers found
SGLT2 inhibitors and GLP-1 receptor agonists provide multi-organ protection across the cardiovascular-kidney-metabolic syndrome spectrum.
Why it matters
Treating these conditions in isolation misses their interconnection — drugs that address multiple organs simultaneously could transform care.
The numbers in context
No specific effect sizes reported; this is a qualitative synthesis of recent CKM literature.
How the study worked
Narrative review synthesizing recent clinical evidence on cardiorenal protective medications in CKM syndrome.
Who was studied
Adults with cardiovascular-kidney-metabolic syndrome
What this study cannot tell us
Narrative review — does not systematically grade evidence quality. Long-term outcomes for combined therapy approaches are still emerging.
How to read the evidence
Review of clinical trial data — individual studies are strong but the review format does not systematically assess bias.
When this study was published
Published in 2025 in JCEM, capturing the latest CKM syndrome management approaches.
The bigger picture
The CKM framework is reshaping how clinicians think about metabolic disease — from treating individual conditions to managing an interconnected syndrome.
Questions still open
- Should SGLT2 inhibitors and GLP-1 drugs be combined routinely in CKM patients?
- Which CKM stage benefits most from early pharmacological intervention?
Common questions
What is CKM syndrome?
Can one medication treat heart, kidney, and metabolic problems together?
Read the original research
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.
The Journal of clinical endocrinology and metabolism, 110(8), 2105-2122
Citation
Pohlman, Neal; Patel, Prem N; Essien, Utibe R; Tang, Jasmyn J; Joseph, Joshua J. (2025). Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.. The Journal of clinical endocrinology and metabolism, 110(8), 2105-2122. https://doi.org/10.1210/clinem/dgaf295